This, in the context of the approval of tissue-agnostic therapies beyond GI tumors, like pembrolizumab for microsatellite instability (MSI) and high tumor mutational burden (TMB-H) tumors and larotrectinib or entrectinib for NTRK1-3 fusions, further contributes to redefining the traditional boundaries between tumor type and therapeutic strategy [12,13]. Here, NTRK1 is linked to neoplasm.